Insider Trades: 5 ASX 200 directors bought these stocks last week
In a relatively quiet week for insider transaction volumes, directors from ARB Corp, Orora and more bought a few small parcels.
Source: Shutterstock
Mentioned
Welcome back to the Insider Trades Series – a weekly summary of on-market ASX 200 director transactions valued at more than $10,000. The trades have all taken place between 16-21 May 2025. Directors have up to 5 business days to notify the ASX of their trades.
Last week, director transaction activity remained subdued, with all transactions involving non-executive directors. Activity has been lacklustre since late March and a brief spike following the 3-April Liberation Day selloff.
Top ASX 200 insider transactions
Code | Company | Date | Director | Type | Price | Value |
|---|---|---|---|---|---|---|
ARB Corporation | 21/05/25 | Buy | $30.06 | $60,120 | ||
Orora | 19/05/25 | Buy | $1.91 | $47,837 | ||
Iress | 16/05/25 | Buy | $8.49 | $24,994 | ||
Commonwealth Bank of Australia | 21/05/25 | Buy | $175.12 | $16,461 | ||
ANZ Group Holdings | 19/05/25 | Buy | $28.89 | $14,445 |
Key takeaways
These transactions offer few notable insights. Below is a recap of key catalysts and data for the larger transactions.
ARB Corp shares have declined 25% year-to-date, underperforming due to several headwinds, including slowing Australian aftermarket revenue growth, unhedged foreign exchange exposure, high investment costs, and modest US tariff impacts. UBS views consensus earnings expectations for ARB as overly optimistic, forecasting a 7.7% year-on-year drop in FY25 net profits to $96 million, 5% below market estimates. They highlight a risk of near-term earnings misses, driven by a significant profit decline in the second half of FY25.
Orora shares saw volatility on Thursday, May 15, after reaffirming flat year-on-year 2H25 EBIT. The stock briefly fell 4% but closed 0.5% higher. Orora reported that cans volume growth has stabilised at a long-term run rate of about 4% year-to-date in 2H25, while Saverglass sees modest volume growth, offset by a product mix favouring premium wine and champagne.
The company projects FY25 capex at $285–295 million and depreciation & amortisation at $155–165 million, compared to Macquarie’s March 2025 capex forecast of $314 million. UBS maintained a Neutral rating but lowered their target price from $2.40 to $2.10, citing reallocated corporate overheads and updated depreciation guidance.
